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1 Servicio de Inmunoloǵıa, Hospital Universitario Marqués de Valdecilla, Avenida de Valdecilla s/n, 39008 Santander, Spain
2 Unidad de Enfermedades Infecciosas, Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla,
Universidad de Cantabria, 39011 Santander, Spain
Correspondence should be addressed to J.-Gonzalo Ocejo-Vinyals, jgocejo@humv.es
Received 25 September 2012; Revised 16 November 2012; Accepted 18 November 2012
Academic Editor: José R. Lapa e Silva
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Mannose-binding lectin is a central molecule of the innate immune system. Mannose-binding lectin 2 promoter polymorphisms
and structural variants have been associated with susceptibility to tuberculosis. However, contradictory results among different
populations have been reported, resulting in no convincing evidence of association between mannose-binding lectin 2 and
susceptibility to tuberculosis. For this reason, we conducted a study in a well genetically conserved Spanish population in order to
shed light on this controversial association. We analysed the six promoter and structural mannose-binding lectin 2 gene variants
in 107 patients with pulmonary tuberculosis and 441 healthy controls. Only D variant and HYPD haplotype were significantly
more frequents in controls which would indicate that this allele could confer protection against pulmonary tuberculosis, but this
difference disappeared after statistical correction. Neither the rest of alleles nor the haplotypes were significantly associated with
the disease. These results would indicate that mannose-binding lectin promoter polymorphisms and gene variants would not
be associated with an increased risk to pulmonary tuberculosis. Despite the slight trend of the D allele and HYPD haplotype in
conferring protection against pulmonary tuberculosis, susceptibility to this disease would probably be due to other genetic factors,
at least in our population.
1. Introduction
Tuberculosis (TB) is one of the world’s most important
infectious causes of death worldwide. More than 90 million
TB patients were reported to WHO between 1980 and 2005,
most of them in Asia and sub-Saharan Africa [1]. Spain is one
of the European countries with the highest rates of incidence
and prevalence of TB [2].
Approximately 90%–95% of individuals infected with
Mycobacterium tuberculosis (MTB) are able to mount an
immune response that halts the progression from latent TB
infection to active TB disease. This is one of the main reasons
that would indicate the need to identify and treat all those
with risk factors for TB disease [3, 4].
Susceptibility to TB seems to be multifactorial, and the
development of active disease would probably be the result of
a complex interaction between the host and pathogen
influenced by environmental and genetic factors. Numerous
host genes are likely to be involved in this process [5–7].
Mannose-binding lectin (MBL) is an acute phase protein
primarily produced by the liver. One of its main roles is
to activate the complement system suggesting that it is one
of the most important constituents of the innate immune
system [8–12]. The gene encoding MBL has been associated
with susceptibility to TB and other infectious diseases [8, 13].
The first mutation in MBL2, the gene encoding MBL was
found in 1991 [14]. Three structural mutations, affecting
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codons 52, 54, and 57, in the first exon of the MBL2 gene
(MBL1 is a pseudogene) have been found, and the corre-
sponding alleles were designated D, B, and C, respectively
(A is the wild-type allele for all three positions). Moreover,
three polymorphisms have also been identified in the MBL2
promoter and 5′-untranslated regions: H/L at position−550,
X/Y at position −221, and P/Q at position +4 [15].
The effect of the three structural mutations in the MBL2
first exon involves the impairment of MBL multimerization.
This caused decreasing ligand binding and, consequently,
a lack of complement activation [16]. In general, all these
genetic variants result in a phenotype of low serum MBL
levels, which influences the susceptibility to TB and the
course of different diseases [13, 17, 18].
To date, controversial results have been reported regard-
ing the relationship between structural genetic variants or
polymorphisms of the MBL2 gene and an increased risk of
TB in different populations [19–30]. Several studies have
found a significant association between the frequency of
structural alleles or promoter polymorphisms and serum
MBL levels with susceptibility to TB [20, 23, 24, 26–30] while
others did not find any significant association [19, 21, 25].
Recently a meta-analysis of 17 human trials considering
the effect of MBL2 genotype and/or MBL levels and TB
infection did not found significant association between
MBL2 genotype and pulmonary TB infection [22]. The
majority of studies analysed did not report neither the
MBL2 haplotype nor the promoter polymorphisms. The
aim of our study was to analyse if gene variants, promoter
polymorphisms, haplotypes, or diplotypes could contribute
to increase the risk of active pulmonary TB (PTB) in a human
immunodeficiency virus negative genetically homogeneous
population (Cantabria, Northern Spain), containing newly
diagnosed patients with active disease.
2. Material and Methods
2.1. Study Population. To investigate the possible association
between MBL2 polymorphisms and PTB infection in our
population, we recruited a total of 107 active PTB patients
and 441 randomly selected healthy blood donors from
Cantabria (northern Spain). All of them were HIV negative.
The study was conducted at a 1,200-bed community
and teaching hospital. Both, blood donors (mean age, 48
years; range, 18–65 years; male/female ratio, 1.3) and PTB
patients (mean age, 56 years; range, 23–76 years; male/female
ratio, 1.5) were of Caucasian background. The PTB patients
group was selected from patients admitted to the Infectious
Unit and the Department of Respiratory Medicine (Hospital
Universitario Marqués de Valdecilla) from 2008 to 2011
and who fulfilled clinical, radiological, and bacteriological
criteria of active PTB according the standards for the
diagnosis and classification of TB developed by the American
Thoracic Society and the Centers for Disease Control and
Prevention (http://www.cdc.gov/mmwr/). Diagnosis of PTB
was made clinically and by X-rays and confirmed by bacteri-
ological (microscopy and culture) procedures. We excluded
patients with extrapulmonary TB due to dissemination and
subsequent involvement of single or multiple nonpulmonary
sites. In the same way, we excluded patients with autoim-
mune or neoplastic diseases, chronic renal failure, transplant
individuals, and patients suffering from alcoholism or drug
abuse. Controls had neither previous history of TB nor
contact with infected patients. Furthermore, we ruled out
the presence of active or latent TB in the control group by
performing an interferon-gamma release assay (Quantiferon
TB Gold, Cellestis Ltd., Carnegie, Victoria, Australia). All the
procedures used in the study conformed to the principles
outlined in the Declaration of Helsinki. Informed consent
was obtained and data anonymously recorded. The study
protocol was accepted and approved by the Research Ethics
Board of the Hospital.
2.2. DNA Extraction and Amplification of Genomic DNA for
MBL2 Genotyping. Blood was collected in EDTA-stabilized
tubes in compliance with approved protocols from our
institution. Genomic DNA from patients and controls was
extracted from peripheral blood by using the Maxwell 16
Genomic DNA Purification system. For MBL2 gene ampli-
fication and genotyping, we used the INNO-LiPA MBL2
(Innogenetics Diagnóstica Iberia S.L.U, Barcelona, Spain),
following the manufacturer’s instructions. The INNO-LIPA
MBL2 is a line probe assay, designed for genotyping the 6
variations in the human MBL2 gene (−550G > C, −221G >
C, +4C > T, R52C, G54D, and G57E) which leads to analyse
the seven common haplotypes and the 28 possible resulting
diplotypes.
3. Statistical Analysis
Frequencies of alleles and diplotypes of patients and healthy
controls were estimated by direct counting. Alleles and
genotypic (dyplotypes) frequencies were compared by χ2
test or the Fisher’s exact test when necessary. P values with
Yates correction and odds ratio (OR) with 95% confidence
intervals (CI) were calculated using SPSS version 12.0 (SPSS
Inc, Chicago, IL, USA). P < 0.05 was considered statistically
significant. Hardy-Weinberg equilibrium (HWE) was tested
in patients and controls for all the analysed parameters.
Bonferroni correction for multiple comparisons was applied
in order to avoid false positive results.
For haplotype analysis, frequencies and linkage dise-
quilibrium were calculated trough the expectation max-
imization algorithm using the SNPStats web-based tool
(http://bioinfo.iconcologia.net/SNPstats/). To determine the
linkage disequilibrium between pairs of alleles, we calculated
the D′ statistic. Comparisons between patients and controls
were performed by χ2 test or the Fisher’s exact test consider-
ing each haplotype like an allele.
Statistical power was calculated by using the PS power
and sample size calculation software version 3.0, (http://bios-
tat.mc.vanderbilt.edu/PowerSampleSize).
4. Results and Discussion
4.1. MBL2 Structural Variants, Promoter Polymorphisms,
and Genotypes. Frequencies of MBL2 alleles are shown in
Table 1. All the structural genetic variants and the promoter
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Table 1: Allelic frequencies of MBL2 structural variants and promoter polymorphisms in healthy controls and patients with pulmonary
tuberculosis.
Structural variants Promoter polymorphisms
A B C D L H Y X P Q
Controls
(n = 441) 0.782 0.143 0.008 0.067 0.655 0.345 0.760 0.240 0.815 0.195
PTB Patients





Only D variant showed significant differences between the two groups. The rest of structural and promoter alleles did not show significant differences.
bThe study had 74% power for detecting an odds ratio (OR) ≥ 2.
Table 2: Frequency of MBL2 haplotypes in controls and PTB patients from Cantabria compared with other previously reported populations.
Haplotype
Population
Controls PTB CAN ESK DAN JAP KEN MOZ CHIR MAP WAR
(n = 441) (n = 107) (n = 344) (n = 72) (n = 250) (n = 218) (n = 61) (n = 154) (n = 43) (n = 25) (n = 190)
HYPA 0.28 0.30 0.24 0.81 0.31 0.44 0.08 0.06 0.54 0.38 0.75
LYQA 0.23 0.23 0.22 0 0.19 0.16 0.25 0.27 0.01 0 0.01
LYPA 0.07 0.08 0.08 0.04 0.04 0.07 0.13 0.30 0.02 0.08 0.23
LXPA 0.21 0.23 0.19 0.03 0.26 0.11 0.24 0.13 0.01 0.04 0.01
LYPB 0.14 0.13 0.17 0.12 0.11 0.22 0.02 0 0.42 0.46 0
LYQC 0.01 0.01 0.03 0 0.03 0 0.24 0.24 0 0.04 0
HYPD 0.07 0.02a 0.07 0 0.06 0 0.04 0 0 0 0.003
Hb 0.81 0.82 0.82 0.33 0.79 0.72 0.81 0.76 0.54 0.66 0.39
Controls, healthy population from Cantabria, PTB, patients with pulmonary tuberculosis from Cantabria, CAN, and Gran Canaria p; ESK, Eskimo; DAN,
Danish; JAP, Japanese; KEN, Kenya; MOZ, Mozambique; CHIR, Chiriguano (South America); MAP, Mapuche (South America); WAR, Warlpiri (Australia)
populations.
aP value 0.014 (OR 0.33 and 95% CI 0.13–0.84): frequency of HYPD haplotype in PTB patients versus control subjects from Cantabria.
bAverage heterozygosity of the seven alleles when they were considered together.
polymorphisms were within the range of HWE. The average
heterozygosity in the control group was 0.88 when the seven
alleles of the MBL2 gene were analysed, being this frequency
higher than others previously reported in different popula-
tions [30].
There was no significant difference in the frequencies of
the different promoter polymorphisms. Regarding the struc-
tural variants, only D allele was significantly more frequent
in controls (P = 0.014, OR 0.33, and CI 95% 0.13–0.84), but
this significance disappeared after Bonferroni correction.
Table 2 shows the frequency of the MBL2 haplotypes in
controls and PTB patients from Cantabria compared with
other previously reported populations. As with D struc-
tural variant, HYPD showed the same significant difference
between PTB patients and controls which disappeared after
Bonferroni correction. All the promoter polymorphisms and
structural variants conforming the different haplotypes were
in linkage disequilibrium (P < 2e − 16).
4.2. MBL2 Complete Genotypes (Diplotypes) in PTB Patients
and Healthy Controls. The frequencies of all the possible
combinations of the seven haplotypes that appeared in both
groups are shown in Table 3. No significant differences were
found in any of the complete diplotypes between PTB
patients and healthy controls.
All seven haplotypes were present in both groups follow-
ing the same order of frequency in them, giving rise to 22
different MBL2 diplotypes in our subjects. Eighteen of these
diplotypes were present in both groups, 5 in either the PTB
patients or the control group, and six diplotypes were not
observed in any of the groups.
HYPA was the most frequent haplotype, followed by
LYQA, LXPA, LYPB, LYPA, HYPD, and LYQC, respec-
tively. When we regrouped the 22 observed diplotypes
in all the possible genotypic combinations (structural-
structural, structural-polymorphism, and polymorphism-
polymorphism), we did not find any significant difference
(data not shown).
5. Discussion
Innate immunity is one of the most important barriers
against invading pathogens. The complement system gets
activated when these microorganisms are detected, resulting
in biochemical pathways that lead to the destruction of
the infectious agent. One of these pathways that make up
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P value OR (95% CI)
LYQA/HYPA 17 (15.9) 54 (12.24) 0.40 1.35 (0.75–2.45)
LYQA/LYPB 10 (9.3) 29 (6.58) 0.43 1.46 (0.69–3.11)
LYQA/LYPA 6 (5.6) 19 (4.31) 0.60 1.32 (0.51–3.39)
LYQA/LYQA 3 (2.8) 19 (4.31) 0.59 0.64 (0.19–2.20)
LYQA/HYPD 1 (0.9) 10 (2.27) 0.70 0.41 (0.05–3.21)
LYQA/LYQC 0 (0) 2 (0.45) 1.0 NA NA
LYQC/HYPD 0 (0) 1 (0.23) 1.0 NA NA
LXPA/HYPA 15 (14.0) 45 (10.20) 0.34 1.43 (0.77–2.69)
LXPA/LYQA 10 (9.3) 53 (12.02) 0.54 0.75 (0.37–1.54)
LXPA/LXPA 7 (6.5) 14 (3.17) 0.15 2.14 (0.84–5.43)
LXPA/LYPB 4 (3.7) 31 (7.03) 0.30 0.51 (0.18–1.49)
LXPA/HYPD 3 (2.8) 13 (2.95) 1.0 0.95 (0.27–3.39)
LXPA/LYPA 1 (0.9) 10 (2.27) 0.70 0.41 (0.05–3.21)
LXPA/LYQC 1 (0.9) 2 (0.45) 0.48 2.07 (0.19–23.05)
HYPA/HYPA 10 (9.3) 38 (8.62) 0.96 1.09 (0.53–2.27)
LYPB/HYPA 8 (7.5) 38 (8.62) 0.88 0.86 (0.39–1.89)
LYPB/LYPB 1 (0.9) 7 (1.59) 1.0 0.58 (0.07–4.81)
LYPB/LYQC 1 (0.9) 1 (0.23) 0.35 4.15 (0.26–66.90)
LYPB/HYPD 0 (0) 9 (2.04) 0.22 NA NA
LYPA/HYPA 4 (3.7) 18 (4.08) 1.0 0.91 (1.30–2.75)
LYPA/LYPB 3 (2.8) 4 (0.91) 0.14 3.15 (0.69–14.30)
LYPA/LYPA 1 (0.9) 2 (0.45) 0.48 2.07 (0.19–23.05)
LYPA/LYQC 0 (0) 1 (0.23) 1.0 NA NA
LYPA/HYPD 1 (0.9) 2 (0.45) 0.48 2.07 (0.19–23.05)
HYPD/HYPA 0 (0) 14 (3.17) 0.08 NA NA
HYPD/HYPD 0 (0) 5 (1.13) 0.59 NA NA
∗
Frequencies of the rest of combined diplotypes (LYQC/HYPA, LYQC/
LYQC) were 0 in both groups.
the complement system is the lectin pathway in which MBL
plays the main role. MBL protein is therefore important,
especially in first-line defense against invading pathogens. It
has been reported that low levels of circulating MBL may
predispose against infectious diseases [8, 31, 32].
Structural variants are found at the coding regions of the
MBL2 gene that lead to low or near absent serum MBL levels
in heterozygosis and homozygosis, respectively. Low-serum
levels of MBL are associated with defects in opsonization,
resulting in recurrent infections mainly during infancy
[31]. Due to a strong linkage disequilibrium between the
polymorphisms present in the promotor and the structural
variants in exon 1 of the human MBL2 gene, only seven
common haplotypes have been described (HYPA, LYPA,
LXPA, LYQA, HYPD, LYPB, and LYQC) which give rise
to 28 possible haplotype combinations. The frequencies of
the seven haplotypes vary considerably between populations
[17, 18]. Among haplotypes carrying the wild-type A allele,
HYPA results in the production of higher amounts of MBL,
whereas LXPA is associated with lower serum MBL levels.
Several groups have studied MBL2 genetic variants and
PTB, suggesting a partial protective effect of heterozygosity
for MBL2 variant alleles against PTB [33–35], whereas others
have pointed toward a susceptibility to PTB for homozygous
carriers of MBL2 variant alleles [36].
Previous studies have found controversial results, at least
at a genetic level. Some authors have reported a lower
frequency of allele B in Afro-Americans, but not in Caucasian
or in the so-called “Hispanic” TB patients [28]. However,
other reports have not found any significant differences in the
frequency of structural MBL2 alleles between PTB Caucasian
patients and control subjects. Nevertheless, when they
included the promoter polymorphisms according to high
serum MBL levels (YA/YA, YA/XA, XA/XA, and YA/O), low
MBL levels (XA/O), and deficient MBL individuals (O/O),a
significant difference in diplotype frequency was revealed
[25, 27, 29]. Finally, another study has found a significantly
increased frequency of O/O diplotype of structural polymor-
phism and of Y/Y diplotype of promoter polymorphisms in
HIV-TB+ patients compared with controls [24].
In the present study, we have investigated whether struc-
tural variations or promoter polymorphisms in the MBL2
gene considering them individually of regrouped might be
associated with PTB in Northern Spain. Our results after
statistical correction show that there is no differences neither
in the frequencies of polymorphisms in the promoter and
5′-untranslated region nor in the structural variants of the
exon 1 of the MBL2 gene between PTB patients and control
subjects when we considered them individually.
Lack of concordance of our results and those from
other studies, specifically another Spanish report that studied
MBL2 gene variants in the population from Canary Islands,
[27] could be explained, at least, by the genetic characteristics
of both pathogens and hosts. There are, consequently, two
possibilities to understand these differences among insular
and peninsular Spaniards.
First of all, it should be considered the different ethnic
background of geographically apart populations [37–40].
Genetic studies have demonstrated that an aboriginal African
background still persists in inhabitants from Canary Islands.
Estimates of genetic contribution to the Canary Islanders
from their putative parental populations based on mtDNA
and other genetic markers are 43% Berbers, 35% Peninsular
Spaniards, and 21% Guineans (being the Spanish nuclear
contribution due to males and practically all the Berber and
Guinean due to females). On the other hand, Cantabrians, at
the North of the Iberian Peninsula, appear as a semi-isolated
result of an ancient indigenous substrate more or less mixed
with more recent immigrants. This population seems to be a
genetically well-differentiated community, as deduced from
uniparental and autosomal markers, perhaps to a higher
level than their neighbours, the Basques, the most reputed
European isolate on linguistic grounds [41–43].
Secondly, another explanation could be due to the genetic
background within M. tuberculosis because variability among
different strains of M. tuberculosis in their surface, oligosac-
charides, might have led to differences in the MBL levels
associated with resistance or susceptibility against PTB
[27, 44, 45]. Consequently, when geographic variation in
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pathogen polymorphism is superimposed on host genetic
heterogeneity, considerable variation may occur in detectable
allelic association [5]. These factors could explain our
findings in the analysed Northern Spanish population.
6. Conclusion
The results obtained in our study show a significant higher
prevalence of MBL2 D allele and HYPD haplotype in controls
than in PTB patients (6.7% versus 2.3%, P = 0.014, OR 0.33,
and CI 95% 0.13–0.84).
Although after statistical correction, the significance
disappeared; this trend of the P values to significance could
indicate a role of D allele and HYPD haplotype in conferring
protection against PTB. For this reason, we cannot argue that
MBL2 D allele or HYPD haplotype would act as a factor of
resistance to PTB, and susceptibility to this disease would
probably be determined by other environmental and genetic
factors, at least in our population [20, 46–50].
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